Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
904 PLN | +1.01% | +0.56% | -2.27% |
Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.33 for the 2024 fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.27% | 998M | B- | ||
+17.35% | 71.39B | C+ | ||
+5.38% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+0.49% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-3.38% | 3.93B | B- | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEU Stock
- Ratings NEUCA S.A.